1-(5-isoquinolinesulfonyl)-2-methylpiperazine has been researched along with nephrin in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 2 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Anderson, S; Beard, DR; Komers, R; Lotspeich, DF; Oyama, TT; Tikellis, C; Xu, B | 1 |
Higashi, K; Kumagai, H; Kushiyama, T; Miura, S; Oda, T; Oshima, N; Sakurai, Y; Takechi, H; Uchida, T; Watanabe, A; Yamamoto, K | 1 |
2 other study(ies) available for 1-(5-isoquinolinesulfonyl)-2-methylpiperazine and nephrin
Article | Year |
---|---|
Rho kinase inhibition protects kidneys from diabetic nephropathy without reducing blood pressure.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Angiotensin II Type 1 Receptor Blockers; Animals; Blood Pressure; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Epithelial-Mesenchymal Transition; Gene Expression; Kidney; Losartan; Male; Membrane Proteins; Nephrectomy; Protein Kinase Inhibitors; Rats; Rats, Sprague-Dawley; rho-Associated Kinases; Vascular Endothelial Growth Factor A | 2011 |
Protective effects of Rho kinase inhibitor fasudil on rats with chronic kidney disease.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Actins; Angiotensin II Type 1 Receptor Blockers; Animals; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Enzyme Inhibitors; Hypercholesterolemia; Imidazoles; Kidney Glomerulus; Lectins, C-Type; Macrophages; Male; Mannose Receptor; Mannose-Binding Lectins; Membrane Proteins; Microscopy, Electron; Phenotype; Proteinuria; Rats; Receptors, Cell Surface; Renal Insufficiency, Chronic; rho-Associated Kinases; RNA, Messenger; Tetrazoles | 2013 |